P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51

Gespeichert in:

Autor*in:	John Bernat [verfasserIn] Myrl Holida [verfasserIn] Nicola Longo [verfasserIn] Ozlem Goker-Alpan [verfasserIn] Eric Wallace [verfasserIn] Patrick Deegan [verfasserIn] Camilla Tondel [verfasserIn] Francois Eyskens [verfasserIn] Ulla Feldt-Rasmussen [verfasserIn] Derralynn Hughes [verfasserIn] Antonio Pisani [verfasserIn] Ales Linhart [verfasserIn] Rossana Rocco [verfasserIn] Einat Almon [verfasserIn] Sari Alon [verfasserIn] Raul Chertkoff [verfasserIn] David Warnock [verfasserIn] Stephen Waldek [verfasserIn] William Wilcox [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Übergeordnetes Werk:	In: Genetics in Medicine Open ; 1(2023), 1, Seite 100016- volume:1 ; year:2023 ; number:1 ; pages:100016-

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.gimo.2023.100016

Katalog-ID:	DOAJ096280204

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ096280204
003	DE-627
005	20240413145626.0
007	cr uuu---uuuuu
008	240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.gimo.2023.100016 \|2 doi
035			\|a (DE-627)DOAJ096280204
035			\|a (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QH426-470
100	0		\|a John Bernat \|e verfasserin \|4 aut
245	1	0	\|a P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
653		0	\|a Genetics
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Myrl Holida \|e verfasserin \|4 aut
700	0		\|a Nicola Longo \|e verfasserin \|4 aut
700	0		\|a Ozlem Goker-Alpan \|e verfasserin \|4 aut
700	0		\|a Eric Wallace \|e verfasserin \|4 aut
700	0		\|a Patrick Deegan \|e verfasserin \|4 aut
700	0		\|a Camilla Tondel \|e verfasserin \|4 aut
700	0		\|a Francois Eyskens \|e verfasserin \|4 aut
700	0		\|a Ulla Feldt-Rasmussen \|e verfasserin \|4 aut
700	0		\|a Derralynn Hughes \|e verfasserin \|4 aut
700	0		\|a Antonio Pisani \|e verfasserin \|4 aut
700	0		\|a Ales Linhart \|e verfasserin \|4 aut
700	0		\|a Rossana Rocco \|e verfasserin \|4 aut
700	0		\|a Einat Almon \|e verfasserin \|4 aut
700	0		\|a Sari Alon \|e verfasserin \|4 aut
700	0		\|a Raul Chertkoff \|e verfasserin \|4 aut
700	0		\|a David Warnock \|e verfasserin \|4 aut
700	0		\|a Stephen Waldek \|e verfasserin \|4 aut
700	0		\|a William Wilcox \|e verfasserin \|4 aut
773	0	8	\|i In \|t Genetics in Medicine Open \|g 1(2023), 1, Seite 100016-
773	1	8	\|g volume:1 \|g year:2023 \|g number:1 \|g pages:100016-
856	4	0	\|u https://doi.org/10.1016/j.gimo.2023.100016 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S294977442300016X \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2949-7744 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|d 1 \|j 2023 \|e 1 \|h 100016-

Indexfelder

author_variant	j b jb m h mh n l nl o g a oga e w ew p d pd c t ct f e fe u f r ufr d h dh a p ap a l al r r rr e a ea s a sa r c rc d w dw s w sw w w ww
matchkey_str	johnbernatmyrlholidanicolalongoozlemgoke:2023----:06ogemaeynefccopgngliaeladiitrdvr4ekifbyies
hierarchy_sort_str	2023
callnumber-subject-code	QH
publishDate	2023
allfields	10.1016/j.gimo.2023.100016 doi (DE-627)DOAJ096280204 (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a DE-627 ger DE-627 rakwb eng QH426-470 John Bernat verfasserin aut P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Genetics Medicine R Myrl Holida verfasserin aut Nicola Longo verfasserin aut Ozlem Goker-Alpan verfasserin aut Eric Wallace verfasserin aut Patrick Deegan verfasserin aut Camilla Tondel verfasserin aut Francois Eyskens verfasserin aut Ulla Feldt-Rasmussen verfasserin aut Derralynn Hughes verfasserin aut Antonio Pisani verfasserin aut Ales Linhart verfasserin aut Rossana Rocco verfasserin aut Einat Almon verfasserin aut Sari Alon verfasserin aut Raul Chertkoff verfasserin aut David Warnock verfasserin aut Stephen Waldek verfasserin aut William Wilcox verfasserin aut In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016- https://doi.org/10.1016/j.gimo.2023.100016 kostenfrei https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a kostenfrei http://www.sciencedirect.com/science/article/pii/S294977442300016X kostenfrei https://doaj.org/toc/2949-7744 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2023 1 100016-
spelling	10.1016/j.gimo.2023.100016 doi (DE-627)DOAJ096280204 (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a DE-627 ger DE-627 rakwb eng QH426-470 John Bernat verfasserin aut P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Genetics Medicine R Myrl Holida verfasserin aut Nicola Longo verfasserin aut Ozlem Goker-Alpan verfasserin aut Eric Wallace verfasserin aut Patrick Deegan verfasserin aut Camilla Tondel verfasserin aut Francois Eyskens verfasserin aut Ulla Feldt-Rasmussen verfasserin aut Derralynn Hughes verfasserin aut Antonio Pisani verfasserin aut Ales Linhart verfasserin aut Rossana Rocco verfasserin aut Einat Almon verfasserin aut Sari Alon verfasserin aut Raul Chertkoff verfasserin aut David Warnock verfasserin aut Stephen Waldek verfasserin aut William Wilcox verfasserin aut In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016- https://doi.org/10.1016/j.gimo.2023.100016 kostenfrei https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a kostenfrei http://www.sciencedirect.com/science/article/pii/S294977442300016X kostenfrei https://doaj.org/toc/2949-7744 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2023 1 100016-
allfields_unstemmed	10.1016/j.gimo.2023.100016 doi (DE-627)DOAJ096280204 (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a DE-627 ger DE-627 rakwb eng QH426-470 John Bernat verfasserin aut P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Genetics Medicine R Myrl Holida verfasserin aut Nicola Longo verfasserin aut Ozlem Goker-Alpan verfasserin aut Eric Wallace verfasserin aut Patrick Deegan verfasserin aut Camilla Tondel verfasserin aut Francois Eyskens verfasserin aut Ulla Feldt-Rasmussen verfasserin aut Derralynn Hughes verfasserin aut Antonio Pisani verfasserin aut Ales Linhart verfasserin aut Rossana Rocco verfasserin aut Einat Almon verfasserin aut Sari Alon verfasserin aut Raul Chertkoff verfasserin aut David Warnock verfasserin aut Stephen Waldek verfasserin aut William Wilcox verfasserin aut In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016- https://doi.org/10.1016/j.gimo.2023.100016 kostenfrei https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a kostenfrei http://www.sciencedirect.com/science/article/pii/S294977442300016X kostenfrei https://doaj.org/toc/2949-7744 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2023 1 100016-
allfieldsGer	10.1016/j.gimo.2023.100016 doi (DE-627)DOAJ096280204 (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a DE-627 ger DE-627 rakwb eng QH426-470 John Bernat verfasserin aut P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Genetics Medicine R Myrl Holida verfasserin aut Nicola Longo verfasserin aut Ozlem Goker-Alpan verfasserin aut Eric Wallace verfasserin aut Patrick Deegan verfasserin aut Camilla Tondel verfasserin aut Francois Eyskens verfasserin aut Ulla Feldt-Rasmussen verfasserin aut Derralynn Hughes verfasserin aut Antonio Pisani verfasserin aut Ales Linhart verfasserin aut Rossana Rocco verfasserin aut Einat Almon verfasserin aut Sari Alon verfasserin aut Raul Chertkoff verfasserin aut David Warnock verfasserin aut Stephen Waldek verfasserin aut William Wilcox verfasserin aut In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016- https://doi.org/10.1016/j.gimo.2023.100016 kostenfrei https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a kostenfrei http://www.sciencedirect.com/science/article/pii/S294977442300016X kostenfrei https://doaj.org/toc/2949-7744 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2023 1 100016-
allfieldsSound	10.1016/j.gimo.2023.100016 doi (DE-627)DOAJ096280204 (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a DE-627 ger DE-627 rakwb eng QH426-470 John Bernat verfasserin aut P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Genetics Medicine R Myrl Holida verfasserin aut Nicola Longo verfasserin aut Ozlem Goker-Alpan verfasserin aut Eric Wallace verfasserin aut Patrick Deegan verfasserin aut Camilla Tondel verfasserin aut Francois Eyskens verfasserin aut Ulla Feldt-Rasmussen verfasserin aut Derralynn Hughes verfasserin aut Antonio Pisani verfasserin aut Ales Linhart verfasserin aut Rossana Rocco verfasserin aut Einat Almon verfasserin aut Sari Alon verfasserin aut Raul Chertkoff verfasserin aut David Warnock verfasserin aut Stephen Waldek verfasserin aut William Wilcox verfasserin aut In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016- https://doi.org/10.1016/j.gimo.2023.100016 kostenfrei https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a kostenfrei http://www.sciencedirect.com/science/article/pii/S294977442300016X kostenfrei https://doaj.org/toc/2949-7744 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2023 1 100016-
language	English
source	In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016-
sourceStr	In Genetics in Medicine Open 1(2023), 1, Seite 100016- volume:1 year:2023 number:1 pages:100016-
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Genetics Medicine R
isfreeaccess_bool	true
container_title	Genetics in Medicine Open
authorswithroles_txt_mv	John Bernat @@aut@@ Myrl Holida @@aut@@ Nicola Longo @@aut@@ Ozlem Goker-Alpan @@aut@@ Eric Wallace @@aut@@ Patrick Deegan @@aut@@ Camilla Tondel @@aut@@ Francois Eyskens @@aut@@ Ulla Feldt-Rasmussen @@aut@@ Derralynn Hughes @@aut@@ Antonio Pisani @@aut@@ Ales Linhart @@aut@@ Rossana Rocco @@aut@@ Einat Almon @@aut@@ Sari Alon @@aut@@ Raul Chertkoff @@aut@@ David Warnock @@aut@@ Stephen Waldek @@aut@@ William Wilcox @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
id	DOAJ096280204
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096280204</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413145626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.gimo.2023.100016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096280204</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH426-470</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">John Bernat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Genetics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Myrl Holida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Longo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ozlem Goker-Alpan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric Wallace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Deegan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Camilla Tondel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francois Eyskens</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulla Feldt-Rasmussen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Derralynn Hughes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Pisani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ales Linhart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rossana Rocco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Einat Almon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sari Alon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raul Chertkoff</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Warnock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephen Waldek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Wilcox</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Genetics in Medicine Open</subfield><subfield code="g">1(2023), 1, Seite 100016-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:100016-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.gimo.2023.100016</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S294977442300016X</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2949-7744</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="h">100016-</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	John Bernat
spellingShingle	John Bernat misc QH426-470 misc Genetics misc Medicine misc R P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
authorStr	John Bernat
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QH426-470
illustrated	Not Illustrated
topic_title	QH426-470 P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
topic	misc QH426-470 misc Genetics misc Medicine misc R
topic_unstemmed	misc QH426-470 misc Genetics misc Medicine misc R
topic_browse	misc QH426-470 misc Genetics misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Genetics in Medicine Open
hierarchy_top_title	Genetics in Medicine Open
isfreeaccess_txt	true
title	P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
ctrlnum	(DE-627)DOAJ096280204 (DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a
title_full	P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
author_sort	John Bernat
journal	Genetics in Medicine Open
journalStr	Genetics in Medicine Open
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
container_start_page	100016
author_browse	John Bernat Myrl Holida Nicola Longo Ozlem Goker-Alpan Eric Wallace Patrick Deegan Camilla Tondel Francois Eyskens Ulla Feldt-Rasmussen Derralynn Hughes Antonio Pisani Ales Linhart Rossana Rocco Einat Almon Sari Alon Raul Chertkoff David Warnock Stephen Waldek William Wilcox
container_volume	1
class	QH426-470
format_se	Elektronische Aufsätze
author-letter	John Bernat
doi_str_mv	10.1016/j.gimo.2023.100016
author2-role	verfasserin
title_sort	p006: long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in fabry disease: 2-year interim results from bright51
callnumber	QH426-470
title_auth	P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ
container_issue	1
title_short	P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
url	https://doi.org/10.1016/j.gimo.2023.100016 https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a http://www.sciencedirect.com/science/article/pii/S294977442300016X https://doaj.org/toc/2949-7744
remote_bool	true
author2	Myrl Holida Nicola Longo Ozlem Goker-Alpan Eric Wallace Patrick Deegan Camilla Tondel Francois Eyskens Ulla Feldt-Rasmussen Derralynn Hughes Antonio Pisani Ales Linhart Rossana Rocco Einat Almon Sari Alon Raul Chertkoff David Warnock Stephen Waldek William Wilcox
author2Str	Myrl Holida Nicola Longo Ozlem Goker-Alpan Eric Wallace Patrick Deegan Camilla Tondel Francois Eyskens Ulla Feldt-Rasmussen Derralynn Hughes Antonio Pisani Ales Linhart Rossana Rocco Einat Almon Sari Alon Raul Chertkoff David Warnock Stephen Waldek William Wilcox
callnumber-subject	QH - Natural History and Biology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.gimo.2023.100016
callnumber-a	QH426-470
up_date	2024-07-03T19:16:54.923Z
_version_	1803586596949196801
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ096280204</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413145626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.gimo.2023.100016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ096280204</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8bbaafcf70e2430d905395dd7c90e62a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH426-470</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">John Bernat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Genetics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Myrl Holida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Longo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ozlem Goker-Alpan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric Wallace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Deegan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Camilla Tondel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francois Eyskens</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulla Feldt-Rasmussen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Derralynn Hughes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Pisani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ales Linhart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rossana Rocco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Einat Almon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sari Alon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raul Chertkoff</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Warnock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephen Waldek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Wilcox</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Genetics in Medicine Open</subfield><subfield code="g">1(2023), 1, Seite 100016-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:100016-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.gimo.2023.100016</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8bbaafcf70e2430d905395dd7c90e62a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S294977442300016X</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2949-7744</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="h">100016-</subfield></datafield></record></collection>
score	7.400753

Nicht das Richtige dabei?

Schreiben Sie uns!

P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?